Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS

Multiple Sclerosis

Volumn 13, Issue 9, 2007, Pages 1086-1094

  Tomassini, V ^a   De Giglio, L ^a   Reindl, M ^b   Russo, P ^c   Pestalozza, I ^a   Pantano, P ^a   Berger, T ^b   Pozzilli, Carlo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Clinically isolated syndrome; MBP antibodies; MOG antibodies; MRI; Multiple sclerosis; Relapse

Indexed keywords

ANTIBODY; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYELIN ASSOCIATED GLYCOPROTEIN; OLIGODENDROCYTE MYELIN GLYCOPROTEIN; OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICALLY ISOLATED SYNDROME; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE COURSE; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RELAPSE; RISK ASSESSMENT; BLOOD; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; EPIDEMIOLOGY; FOLLOW UP; IMMUNOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN BASIC PROTEINS; MYELIN-ASSOCIATED GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 39549088973     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507077622     Document Type: Article

References (31)

1. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
2. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disabilityfrom multiple sclerosis. N Engl J Med 2002; 346: 158-64.
3. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
4. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon beta-1a therapy initiate during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
5. CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002; 59: 998-1005.
6. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo, L. Axonal transaction in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
7. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of autoantigen. Nature 1992; 358: 155-57.
8. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95.
9. Ozawa K, Suchanek G, Breitschopf H, Bruck W, Budka H, Jellinger K et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994; 117: 1311-22.
10. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple Sclerosis: in situ evidence for antibody and complement-mediated demyelination. Ann Neurol 1998; 43: 465-71.
11. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicate heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259-74.
12. Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999; 122: 2047-56.
13. Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler 2001; 7: 285-89.
14. Kerlero de Rosbo N, Honegger P, Lassmann H, Matthieu JM. Demyelination induced in aggregating brain cell cultures by amonoclonal antibody against myelin/oligodendrocyte glycoprotein. J Neurochem 1990; 55: 583-87.
15. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I et al. Anti-myelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349: 139-45.
16. Lim ET, Berger T, Reindl M, Dalton CM, Fernando K, Keir G et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005; 11: 492-494.
17. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-27.
18. Pestalozza IF, Pozzilli C, Di Legge S, Piattella MC, Pantano P, Caramia F et al. Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome. Mult Scler 2005; 114: 390-94.
19. Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988; 38: 1822-25.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
21. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH et al. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-69.
22. Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodlesterase in the CNS of adult rats. J Neurochem 1989; 52: 296-304.
23. Pittock SJ, Reindl M, Achenbach S, Berger T, Bruck W, Konig F et al. MOG antibodies in pathologically proven MS: Frequency, Stability and Clinicopathologic Correlations. Mult Scler (in press).
24. Barkhof F, Rocca M, Francis G, Van Waesberghe JH, Uitdehaag BM, Hommes OR et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 2003; 53: 718-24.
25. Dalton CM, Brex PA, Miszikiel KA, Hickman SJ, MacManus DG, Plant GT et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002; 52: 47-53.
26. Tintoré M, Rovira A, Río J, Nos C, Grive E, Sastre-Garriga J et al. New diagnostic criteria for multiple sclerosis, application in first demyelinating episode. Neurology 2003; 60: 27-30.
27. Swanton JK, Fernando KT, Dalton CM, Miszkiel KA, Thompson AJ, Plant GT, Miller DH et al. Modification of MRI criteria for MS in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006; 77: 830-33.
28. Kuhle J, Lindberg RLP, Hoffman F. Wu S, E Radü W, Kappos L. Anti-myelin antibodies in clinically isolated syndromes correlate with inflammation and conversion to multiple sclerosis. Mult Scler 2005; 11: (suppl 1) 502.
29. Rauer S, Euler B, Reindl M, Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 2006; 77: 739-42.
30. Kuhle J, Kappos L, Pohl C, Mehling M, Edan G, Freedman M et al. Prognostic relevance of antimyelin antibodies and progression to Multiple Sclerosis. N Engl J Med (2007); 356: 371-78
31. Pelayo R, Tintoré M, Montalban X, Rovira A, Espelo C, Reindl M et al. Antimyelin antibodies with no progression to Multiple Sclerosis. N Engl J Med (2007); 356: 426-28.